Search the Newsreel

CSTL (CSTL) files notice to sell 24,908 common shares on NASDAQ

A holder of CSTL common stock has filed a notice of intent to sell up to 24,908 shares on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services. The indicated aggregate market value of these shares is $741,493.72, and they originated from restricted …

Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction

Castle Biosciences (NASDAQ: CSTL) raised its full-year outlook after exceeding second-quarter expectations, primarily driven by strong performance from its DecisionDx-Melanoma and TissueCypher tests, along with increased physician adoption. The DecisionDx-Melanoma test continues to be a key growth driver, showing mid- to high-single-digit volume growth, …

Wasatch Advisors LP Sells 175,687 Shares of Castle Biosciences, Inc. $CSTL

Wasatch Advisors LP significantly reduced its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by selling 175,687 shares, representing a 38.6% decrease, and now holds 279,349 shares valued at approximately $6.66 million. Despite this reduction by Wasatch Advisors, institutional investors collectively own 92.6% of CSTL. The …

Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 20,356 Shares of Stock

Castle Biosciences insider Derek Maetzold sold 20,356 shares of the company's stock for over $633,000, reducing his ownership by nearly half. This sale was executed under a pre-arranged Rule 10b5-1 trading plan. The company recently reported better-than-expected quarterly results, and analysts maintain a "Moderate …

Tobin Juvenal Sells 1,301 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Tobin Juvenal, an insider at Castle Biosciences (NASDAQ:CSTL), sold 1,301 shares of the company's stock for approximately $49,945, reducing his position by 1.65%. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan. Despite insider sales, Castle Biosciences' recent quarterly results exceeded …

Dimensional Fund Advisors LP Sells 104,038 Shares of Castle Biosciences, Inc. $CSTL

Dimensional Fund Advisors LP reduced its stake in Castle Biosciences (NASDAQ:CSTL) by 9.1%, selling 104,038 shares but still retaining over 1 million shares valued at approximately $25.5 million. This comes as Castle Biosciences exceeded Q1 revenue and EPS expectations, reporting $99.86 million in revenue …

Castle Biosciences (NASDAQ:CSTL) COO Sells 8,586 Shares of Stock

Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal Sells 19,040 Shares

Tobin Juvenal, Chief Commercial Officer of Castle Biosciences (CSTL), sold 19,040 shares of the company's stock for approximately $556,158. This transaction is part of a broader trend of insider selling at Castle Biosciences, with 50 insider sells and zero buys over the past year. …

BTIG raises Castle Biosciences stock price target on strong revenue

BTIG has increased its price target for Castle Biosciences (CSTL) to $44 from $40, maintaining a Buy rating, citing the company's strong 20% revenue beat and 20% growth. This performance was primarily driven by the TissueCypher franchise, with significant volume increases. Despite the stock …

BTIG Research Forecasts Strong Price Appreciation for Castle Biosciences (NASDAQ:CSTL) Stock

CFO Awards honoree Frank Stokes of Castle Biosciences Inc.

Frank Stokes of Castle Biosciences Inc. has been recognized as an honoree for the Houston Business Journal's 2026 CFO Awards. The article highlights Stokes as one of several distinguished individuals acknowledged for their financial leadership. Other honorees include Frank Wilson IV, Ebru Akyildiz, Stephanie …

Castle Biosciences 2026: Revenue $103.55M, EPS ($0.07) — 10-Q Summary

Castle Biosciences (CSTL) reported its 2026 financial results, showing revenue of $103.55 million, an increase from $86.19 million in the previous year. However, the company posted a net loss of ($2.06 million) and diluted EPS of ($0.07), a decline from the prior year's net …

Castle Biosciences, Inc. Stock 12‑Month Price Target Raised to $43.56, Implies 63% Upside

Castle Biosciences, Inc. (CSTL) has seen its average 12-month price target raised to $43.56 from $42.78 by 9 analysts, implying a potential upside of approximately 63% from its July 30 closing price. The consensus rating for the stock remains a "Buy" across all covering …

CSTL (CSTL) insider schedules potential $630,000 sale of 22,500 shares

An affiliate of CASTLE BIOSCIENCES INC (CSTL) has filed a Form 144 to sell 22,500 shares of common stock, with an aggregate market value of $630,000. The shares, originating from various equity compensation grants including Restricted Stock Units and Restricted Stock Awards, are scheduled …

Renaissance Technologies LLC Has $13.08 Million Stock Holdings in Castle Biosciences, Inc. $CSTL

Form 144 Castle Biosciences For: 1 August By Investing.com

This article announces the filing of Form 144 for Castle Biosciences (CSTL) on August 1st. It provides a brief mention of the company's stock performance, showing a 4.52% increase. The content largely consists of market data, trending stocks, and various financial tools provided by …

Castle Biosciences (CSTL) Stock Climbs On Higher Sales Outlook Despite Margin Pressure

Castle Biosciences (CSTL) stock saw a 4.5% jump after its Q2 earnings report, driven by a 20% revenue increase to US$103.5m and an uplifted full-year sales guidance, despite reporting a small net loss. The market appears to be prioritizing the strong top-line growth and …

Castle Biosciences raises 2026 revenue guidance to $365M-$375M as TissueCypher volume trends toward 50%-52% growth

Earnings Call Insights: Castle Biosciences (CSTL) Q2 2026 MANAGEMENT VIEW * "What a great quarter." (Founder, CEO, President & Director Derek Maetzold) "We delivered revenue of $103.5 million, 20% growth compared to the second quarter of 2025." (CEO Maetzold) * "We believe we will …

Key facts: CSTL Q2 Revenue $103.6M; AdvanceAD-Tx 97.8% Concordance

Castle Biosciences (CSTL) reported Q2 revenue of $103.55 million, exceeding estimates of $86.2 million, despite an operating loss of $3.07 million. Additionally, a study revealed that the company's AdvanceAD-Tx testing for atopic dermatitis showed a 97.8% concordance in systemic therapy decisions, significantly higher than …

Castle Biosciences (NASDAQ:CSTL) Releases Quarterly Earnings Results, Beats Expectations By $0.37 EPS

Castle Biosciences (NASDAQ:CSTL) Sees Strong Trading Volume After Earnings Beat

Castle Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CSTL)

Castle Biosciences, Inc. released its Q2 2026 earnings call presentation. The company reported an EPS of -$0.07, beating estimates by $0.34, and revenue of $103.55M, an increase of 20.14% year-over-year, beating estimates by $17.30M. This report accompanies their earnings call from July 31, 2026.

Earnings call transcript: Castle Biosciences tops Q2 2026 estimates, shares jump

Castle Biosciences (CSTL) exceeded second-quarter 2026 profit and revenue estimates, leading to a significant jump in its share price and an increase in full-year sales guidance. The company reported an adjusted loss of 7 cents per share on revenue of $103.5 million, outperforming analyst …

Is Castle Biosciences (CSTL) Undervalued After Q2 Earnings Miss? GF Score: 81/100, Revenue at $103.5 Million

Castle Biosciences Reports Second Quarter 2026 Results

Earnings Flash (CSTL) Castle Biosciences Posts Q2 Adjusted EPS -$0.07, vs. FactSet Est of -$0.41

Castle Biosciences (CSTL) reported Q2 adjusted EPS of -$0.07, significantly outperforming FactSet's estimate of -$0.41. The company also posted Q2 revenue of $103.5 Million, surpassing the FactSet estimate of $86.2 Million. This positive earnings flash comes alongside other recent company news, including Health Department …

Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates

Castle Biosciences, Inc. (CSTL) reported a Q2 loss of $0.07 per share, significantly beating the Zacks Consensus Estimate loss of $0.44 due to non-recurring items. The company also surpassed revenue estimates with $103.55 million, an 18.61% beat, continuing a trend of outperforming revenue expectations …

Castle Biosciences CEO Maetzold sells $237,682 in company stock

Castle Biosciences CEO Derek J. Maetzold sold $237,682 worth of company stock through direct sales and various trusts on July 27, 2026, under a Rule 10b5-1 trading plan. Despite the sales, Maetzold also acquired 6,214 shares by exercising vested stock options. The company is …

Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells $150,130.24 in Stock

Castle Biosciences (NASDAQ:CSTL) insider Derek Maetzold sold 6,214 shares of the company's stock, totaling $150,130.24, under a pre-arranged Rule 10b5-1 plan. This transaction reduced his ownership by 22.44%. The company's stock was trading up 2.4% at $24.46, and analysts maintain a "Moderate Buy" consensus …

Castle Biosciences Inc (CSTL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Castle Biosciences Inc (CSTL), noting its current valuation score of 8.65, which ranks it 75th in the Healthcare Equipment & Supplies industry. The P/E ratio stands at -58.82, significantly below its recent high and above its recent …

Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Moderate Buy" by Analysts

Castle Biosciences, Inc. (NASDAQ:CSTL) has received an average "Moderate Buy" recommendation from analysts, with a 12-month target price of $42.43. While the company met EPS expectations at -$0.49 and exceeded revenue estimates with $84.23 million, it remains unprofitable. Insider activity shows recent sales of …

Castle Biosciences Inc (CSTL) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Castle Biosciences Inc's (CSTL) financial health, noting its current score of 7.55 and ranking within the Healthcare Equipment & Supplies industry. It highlights the company's robust financial status but average operating efficiency. The report also details recent quarterly …